^
    CANCER:

    Neuroblastoma





    Show legend
    Group by Gene:
    Include preclinical:

    naxitamab
    		0
    GD2 ganglioside inhibitor
    dinutuximab beta
    dinutuximab
    1
    Alkylating agent
    melphalan
    cyclophosphamide
    2
    Topoisomerase II inhibitor
    doxorubicin hydrochloride
    3
    Ornithine decarboxylase inhibitor
    eflornithine
    4
    ALK inhibitor
    crizotinib
    alectinib
    5
    WEE1 inhibitor
    AZD1775
    6
    ROS1 inhibitor, ALK inhibitor
    lorlatinib
    7
    Bcr-abl tyrosine kinase inhibitor, DNA synthesis inhibitor, mTOR inhibitor, Src kinase inhibitor, c-KIT inhibitor, PDGFR β antagonist, EphA2 receptor antagonist
    dasatinib + temozolomide + sirolimus
    8
    ROS1 inhibitor, PTPN11 inhibitor, ALK inhibitor
    lorlatinib + TNO155
    9
    DNA synthesis inhibitor
    cisplatin
    10
    ATR inhibitor
    AZD6738
    11
    LRRK2 inhibitor, ALK inhibitor
    TAE-684
    12
    HDAC inhibitor, EZH2 inhibitor
    panobinostat + GSK2816126
    13
    BRD3 inhibitor, BRD4 inhibitor, BRD2 inhibitor
    OTX015
    14
    BET inhibitor, HDAC inhibitor
    JQ-1 + panobinostat
    15
    ALK inhibitor, EGFR inhibitor
    brigatinib
    16
    ALK inhibitor, IGF-1R inhibitor
    AZD3463
    17
    MEK inhibitor
    binimetinib
    18
    ROS1 inhibitor, Trk inhibitor, ALK inhibitor, Multi-tyrosine kinase inhibitor
    repotrectinib
    19
    PTPN11 inhibitor, ALK inhibitor
    crizotinib + TNO155
    ceritinib + TNO155
    20
    ERK2 inhibitor, ERK1 inhibitor
    ASN007
    21
    Chk1 inhibitor, PARP inhibitor
    olaparib + MK-8776
    22
    Aurora kinase A inhibitor, Bcl2 inhibitor
    venetoclax + LY3295668
    23
    CDK9 inhibitor
    KB-0742
    24
    CDK9 inhibitor, P-TEFb inhibitor
    VIP152
    25
    FGFR2 inhibitor, FGFR inhibitor, FGFR1 inhibitor, FGFR3 inhibitor, ROS1 inhibitor, ALK inhibitor, FGFR4 inhibitor
    lorlatinib + erdafitinib
    26
    ROS1 inhibitor, ALK inhibitor, Multi-tyrosine kinase inhibitor
    ponatinib + lorlatinib
    27
    DLL3-targeted antibody-drug conjugate, DNA replication inhibitor
    rovalpituzumab tesirine
    28
    DNA replication inhibitor, DLK1-targeted antibody-drug conjugate
    ADCT-701
    29
    B7-H3-targeted antibody-drug conjugate, DNA replication inhibitor
    MGC018
    30
    CAR-T immunotherapy
    CAR-T immunotherapy
    31
    B7-H3-targeted antibody-drug conjugate
    B7-H3-targeted antibody-drug conjugate
    32
    DHODH inhibitor
    DHODH inhibitor
    No biomarker
    ALK positive
    ALK mutation
    ALK R1275Q
    ALK D1091N
    ALK F1174L
    ALK amplification
    ALK F1245C
    ALK F1174C
    ATRX mutation
    MYCN positive
    MYCN amplification
    CD276 expression
    TERT rearrangement
    PGBD5 overexpression
    NRAS Q61K
    MYC amplification + ALK F1174L
    PGBD5 underexpression
    DLL3 underexpression
    DLK1 expression
    DLL3 expression
    ALK rearrangement + ALK R1275Q + TP53 mutation
    MYCN amplification + ALK rearrangement
    MYCN amplification + ALK F1174V
    NF1 underexpression
    MYCN amplification + ALK F1174L
    MYCN amplification + ALK R1275Q
    ETV6-NTRK3 fusion